SCHEMBL6958985

SCHEMBL6958985

CC(C)Nc1ccc(OCc2ccncc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.49
MAOB P27338 1/20 0.47
KCNH2 Q12809 1/20 0.47
GRIN2B Q13224 1/20 0.47
ADAMTS4 O75173 1/20 0.45
MMP13 P45452 1/20 0.45
CYP27B1 O15528 1/20 0.45
CYP24A1 Q07973 1/20 0.45
ADAM17 P78536 2/20 0.45
ADAM10 O14672 1/20 0.45
MMP3 P08254 1/20 0.45
SYK P43405 1/20 0.44
APP P05067 1/20 0.44
MAPK14 Q16539 1/20 0.44
CTSL P07711 1/20 0.43
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
LTA4H P09960 1/20 0.43
MAPT P10636 1/20 0.43
NPC1 O15118 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7468581 0.83 LTA4H (0.58) MAOBLTA4HMAPTNPC1RAB9A
SCHEMBL22874544 0.82 MAOB (0.51) MAOBAPPLTA4HMAPTNPC1
SCHEMBL22874652 0.82 MAPK1 (0.52) ADAMTS4MMP13NPC1RAB9ASMN1; SMN2
SCHEMBL9975272 0.81 APP (0.65) F2MAOBKCNH2GRIN2BCYP27B1
SCHEMBL22967580 0.81 MAOB (0.56) MAOBAPPMAPTNPC1RAB9A
SCHEMBL22967401 0.81 MAOB (0.56) MAOBAPPNPC1RAB9AAR
SCHEMBL19223054 0.80 MEN1 (0.54) APPLTA4HMAPTNPC1RAB9A
SCHEMBL9021090 0.79 LTA4H (0.55) ADAMTS4MMP13LTA4HNPC1RAB9A
SCHEMBL22874670 0.79 F2 (0.57) F2MAOBKCNH2GRIN2BCYP27B1
SCHEMBL8351092 0.78 TSHR (0.59) MAPTSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3760633-B1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2021-12-15 EP disclosed
US-8349857-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2013-01-08 US disclosed
US-8349857-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2013-01-08 US disclosed
US-8202879-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-06-19 US disclosed
US-20120123114-A1 QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-05-17 US disclosed
US-20120123114-A1 QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-05-17 US disclosed
US-20090143414-A1 Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity SHIONOGI & CO., LTD. (JP) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143414-A1 Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity ERBB2, EGFR, ABL1 F2 2621/4885MAOB 781/4885KCNH2 1995/4885
US-20120123114-A1 QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY ERBB2, EGFR, ABL1 F2 2621/4885MAOB 781/4885KCNH2 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.